
PAND
Healthcare · Biotechnology · $1.77B market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2021
EPS trend, 90 days to now · -2.9% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 3 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 12, 2021 | After the close | -0.47 | 0.54 | +214.9% |
| Nov 16, 2020 | After the close | -0.44 | -0.51 | -15.9% |
| Aug 31, 2020 | After the close | -0.31 | -0.40 | -30.6% |
Pandion Therapeutics, Inc., a clinical stage biopharmaceutical company, develops various therapeutics to address the unmet needs of patients suffering from autoimmune diseases. Its lead product candidate is PT101, an effector module comprising an engineered variant of wild-type interleukin-2 (IL-2) fused to a protein backbone that is in Phase 1a clinical trials for the treatment of various autoimmune and…